Syngene International had informed the exchanges late last night that Syngene USA has completed the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations ...

Syngene International, operating in the Medical Research Services sector and classified as a Midcap on the BSE, currently has its share price at ₹701.3. The stock has experienced fluctuations ...

As of March 10, Syngene International Ltd. announces its first biologics facility purchase in the USA. The site houses several monoclonal antibody (mAbs) production lines. Syngene USA Inc., a ...